Scrotal Irradiation in Primary Testicular Lymphoma: Review of the Literature and In Silico Planning Comparative StudyBrouwer, C. L., Wiesendanger, E. M., van der Hulst, P. C., van Imhoff, G. W., Langendijk, J. A. & Beijert, M., 1-Feb-2013, In : International Journal of Radiation Oncology Biology Physics. 85, 2, p. 298-308 11 p.
Research output: Contribution to journal › Review article › Academic › peer-review
We examined adjuvant irradiation of the scrotum in primary testicular lymphoma (PTL) by means of a literature review in MEDLINE, a telephone survey among Dutch institutes, and an in silico planning comparative study on scrotal irradiation in PTL.
We did not find any uniform adjuvant irradiation technique assuring a safe planning target volume (PTV) coverage in published reports, and the definition of the clinical target volume is unclear. Histopathologic studies of PTL show a high invasion rate of the tunica albuginea, the epididymis, and the spermatic cord. In retrospective studies, a prescribed dose of at least 30 Gy involving the scrotum is associated with best survival. The majority of Dutch institutes irradiate the whole scrotum without using a planning computed tomography scan, with a single electron beam and a total dose of 30 Gy. The in silico planning comparative study showed that all evaluated approaches met a D-95% scrotal dose of at least 85% of the prescription dose, without exceeding the dose limits of critical organs. Photon irradiation with 2 oblique beams using wedges resulted in the best PTV coverage, with a mean value of 95% of the prescribed dose, with lowest maximum dose.
Adjuvant photon or electron irradiation of the whole scrotum including the contralateral testicle with a minimum dose of 30 Gy is recommended in PTL. Computed tomography-based radiation therapy treatment planning with proper patient positioning and position verification guarantees optimal dose coverage. (C) 2013 Elsevier Inc.
|Number of pages||11|
|Journal||International Journal of Radiation Oncology Biology Physics|
|Publication status||Published - 1-Feb-2013|
- NON-HODGKINS-LYMPHOMA, DOXORUBICIN-BASED THERAPY, LARGE-CELL LYMPHOMA, MALIGNANT-LYMPHOMA, EXTRANODAL LYMPHOMA, PROGNOSTIC-FACTORS, GONADAL-FUNCTION, GROUP EXPERIENCE, NORMAL TISSUE, TESTIS